[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fibrosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fibrosis":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,44,80,112,140,161,191,212,247,272,319,346],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":20,"conditions":21,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100464686","screening-and-follow-up-in-patients-with-hiv-infection-combined-with-metabolic-associated-fatty-liver-disease-100464686",false,"NCT05330923","Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease","Inclusion Criteria:\n\n* Newly treated or treated AIDS patients;\n* Regular follow-up visits to the hospital, medication compliance is good;\n* Patients or their family members were willing to participate in the study by understanding the study plan and providing written informed consent.\n\nExclusion Criteria:\n\n* Unable to complete the position requirements of ultrasonic examination (lying flat) due to mobility difficulties;\n* Patients have poor compliance and cannot follow up regularly or take medicine on time;\n* Patients or family members cannot understand the conditions and objectives of the study;\n* Other conditions considered unsuitable for inclusion by the investigator.","ALL",{"count":17,"type":18},2000,"ESTIMATED","OBSERVATIONAL","Acquired immunodeficiency syndrome (AIDS) remains a severe global infectious disease, with over 38 million people living with HIV and around 35 million cumulative deaths worldwide by 2023; approximately 1.24 million HIV-positive individuals and 100,000 new infections are reported annually in China. Widespread use of HAART has prolonged HIV patients' survival and reduced AIDS-related mortality, yet non-AIDS comorbidities dominated by chronic liver disorders, particularly metabolic dysfunction-associated fatty liver disease (MAFLD), have become a major challenge in long-term HIV management. Triggered by elevated blood lipids from lifestyle, antiretroviral agents and inherited metabolic factors, MAFLD initiates with hepatic steatosis and may progress to NASH, liver fibrosis, cirrhosis and even hepatocellular carcinoma (HCC) without timely intervention. HIV-positive patients develop more severe MAFLD progression than HIV-negative counterparts; existing biopsy data shows 91% of ART-treated HIV patients have NAFLD, among whom 65% suffer from NASH complicated with liver fibrosis.\n\nFatty liver prevalence keeps rising with younger onset age in China, which highlights the necessity of early screening. Liver biopsy, the historical diagnostic gold standard for liver injury grading, is restricted by invasiveness, bleeding risks and poor reproducibility. Transient elastography (TE), a novel non-invasive ultrasonic technique, quantifies hepatic steatosis via the ultrasound attenuation parameter (UAP) and liver fibrosis via liver stiffness measurement (LSM), and has been validated and guideline-endorsed for multiple chronic liver diseases globally. Published foreign data report 35%, 42% and 22% prevalence of NAFLD, NASH and fibrosis in PLWH, while domestic evidence on HIV-associated MAFLD is limited, especially liver-related discrepancies among varied ART regimens. With the implementation of China's new medical insurance policy, numerous patients are shifting from non-INI regimens to once-daily single-tablet INSTI STR regimens, whose hepatic and lipid impacts remain unclear. This study targets early detection of HIV patients with concomitant fatty liver to optimize management strategies and improve clinical outcomes.\n\nOur preliminary cohort at Peking Union Medical College Hospital included 188 virologically suppressed HIV patients on ART, 56.9% (107\u002F188) of whom developed fatty liver (mild:27.1%, moderate:19.7%, severe:10.1%). Liver fibrosis (LSM≥7.3 kPa) was found in 12.8% (24\u002F188) subjects, with 1.1% having advanced cirrhosis, and no significant inter-group difference in fatty liver incidence was noted between INSTI and NNRTI recipients. These findings lay a foundation for early diagnosis and follow-up intervention of metabolic liver disease among HIV-infected populations.",[22,23,24,25],"Nonalcoholic Fatty Liver Disease","Nonalcoholic Steatohepatitis","Fibrosis","HIV\u002FAIDS",[27,28,29,30],"integrase inhibitors","non-nucleoside reverse transcriptase inhibitors","transient elastography","iLivTouch","RECRUITING","2026-06-02",{"date":34,"type":35},"2026-06-04","ACTUAL",{"date":37,"type":35},"2022-01-01",{"date":39,"type":18},"2029-06-01",{"name":41,"class":42},"Peking Union Medical College Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":65,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":43},"100618558","phase-2-a-study-of-mosliciguat-in-combination-with-inhaled-treprostinil-in-ph-ild-100618558","NCT07333183","A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD","An Open-Label, Phase 2 Study Evaluating the Safety of Mosliciguat in Combination With Inhaled Treprostinil in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease","Inclusion Criteria:\n\n* Participants willing and able to provide informed consent\n* Participants on inhaled treprostinil\n* Participants with diagnosis of Interstitial Lung Disease (ILD). Diagnosis will be confirmed by a high-resolution computerized tomography (HR-CT) scan showing diffuse parenchymal disease. Eligible diagnosed diseases include:\n\n  1. Idiopathic interstitial pneumonia (IIP)\n  2. Chronic hypersensitivity pneumonitis\n  3. ILD associated with connective tissue disease (CTD) with a forced vital capacity (FVC) \\\u003C 70% of predicted\n* Confirmed pulmonary hypertension (PH) by right heart catheterization (RHC).\n* Ability to perform 6MWD ≥100 meters.\n\nExclusion Criteria:\n\n* Diagnosis of PH Group 1 (eg. pulmonary arterial hypertension), Group 2 (related to left-heart dysfunction), Group 4 (eg, chronic thromboembolic pulmonary hypertension), or Group 5 (eg, unclassified).\n* Exacerbation of underlying lung disease within 28 days prior to randomization.\n* Initiation of pulmonary rehabilitation within 28 days prior to randomization.\n* Receiving \\>10 L\u002Fmin of oxygen supplementation by any mode of delivery at rest at Baseline.\n* History or intolerance to or lack of efficacy with mosliciguat or sGC stimulators or activators.\n* Receipt of investigational, or experimental therapy within 42 days OR 5 half-lives prior to randomization.\n\nNote: Other inclusion and exclusion criteria may apply.","18 Years","85 Years",{"count":54,"type":18},20,"INTERVENTIONAL",[57],"PHASE2","This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.",[60,61,62,63,64,24],"Pulmonary Hypertension","Interstitial Lung Disease (ILD)","Lung Diseases","Vascular Diseases","Cardiovascular Diseases",[66,67,68,69],"PH","ILD","6 Minute Walk Test","mosliciguat","2026-04-18",{"date":72,"type":35},"2026-04-22",{"date":74,"type":35},"2025-12-23",{"date":76,"type":18},"2028-01",{"name":78,"class":79},"Pulmovant, Inc.","INDUSTRY",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":55,"phases":90,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100506446","evaluation-of-the-medical-benefit-of-spa-therapy-on-fibrosis-after-radiotherapy-for-breast-cancer-or-uadt-upper-aerodigestive-tract-cancer-100506446","NCT05874492","Evaluation of the Medical Benefit of Spa Therapy on Fibrosis After Radiotherapy for Breast Cancer or UADT (Upper Aerodigestive Tract) Cancer","Evaluation of the Medical Benefit of a Spa Therapy on the Evolutionary Genius of Late Sequelae Fibrosis After Radiotherapy for Breast Cancer or UADT (Upper Aerodigestive Tract) Cancer in Remission","FIBROTHERME","Inclusion Criteria:\n\n* Age ≥ 18 years\n* In situ or invasive breast cancer or cancer of the upper aerodigestive tract\n* DLQI ≥ 6 (at least moderate effect on patient's life)\n* General status WHO 0-1\n* Radiotherapy completed at least 6 months ago (with no maximum post radiotherapy delay)\n* Unilateral breast radiotherapy for breast cancer patients\n* Skin or soft tissue toxicity (- modules: Skin atrophy, fibrosis of deep connective tissues, fibrosis of superficial soft tissues) CTCAE v4.0 grade ≥ 2\n* No inflammatory or infectious flare at inclusion\n* Female of childbearing potential: negative urine pregnancy test at inclusion\n* Patient informed and signed consent\n* Affiliation to a social security systeme or equivalent\n\nExclusion Criteria:\n\n* Progressive phase of cancer\n* Metastatic disease\n* Patient undergoing specific treatment for breast cancer (except adjuvant hormone therapy and\u002For adjuvant herceptin)\n* Bilateral breast\u002Fparietal radiotherapy\n* Breast prosthesis wearer for breast cancer patients\n* Patient with a tracheostomy for patients with head and neck cancer\n* Obvious skin ulceration in the site of interest\n* Contraindication to spa treatment (acute inflammatory disease, active infections, heart failure with NYHA stage \\> 1, chronic respiratory failure, labile hypertension, bullous disease)\n* Chronic progressive dermatological disease\n* Women who are pregnant or likely to become pregnant within 6 months or who are breastfeeding\n* Persons deprived of liberty or under guardianship",{"count":89,"type":18},110,[91],"NA","FIBROTHERME is a comparative, controlled, randomized, multicenter and simple blinded (investigator) trial.\n\nThe aim of this study is to evaluate the medical benefit in terms of quality of life on the dermatological sequelae of fibrosis 6 months after a dermatologically oriented spa therapy in patients with severe late reactions affecting the skin and\u002For soft tissues at least 6 months after radiotherapy for breast cancer or UADT (Upper Aerodigestive Tract) cancer.",[24,94,95],"Breast Cancer","Head and Neck Cancer",[97,98,99,100,101],"fibrosis","breast cancer","radiotherapy","spa treatment","head and neck cancer","2026-04-08",{"date":104,"type":35},"2026-04-13",{"date":106,"type":35},"2024-01-29",{"date":108,"type":18},"2027-12",{"name":110,"class":42},"Association Francaise pour la Recherche Thermale",13,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":55,"phases":121,"briefSummary":122,"conditions":123,"keywords":127,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":43},"100629197","copper-supplementation-in-cirrhosis-100629197","NCT07471542","Copper Supplementation in Cirrhosis","A Pilot Randomized Controlled Trial to Determine the Biochemical Effect, Safety and Patient Reported Outcomes of Copper Supplementation in Patients With Cirrhosis","Inclusion Criteria:\n\n1. Adult patients age 18 or older with confirmed diagnosis of cirrhosis based on clinical history, exam, imaging, laboratory or histological criteria;\n2. Cirrhosis patients whose serum or plasma Cu are below the normal range (80-155 ug\u002FdL for women and 70-140 ug\u002FdL for men);\n3. Cirrhosis patients whose serum or plasma Cu are in the normal range but exhibit at least one clinical feature that has been associated with Cu deficiency. These include history of infections, unexplained anemia, severe leukopenia, iron overload, unexplained neurological symptoms such as ataxia or myelopathy, coagulopathy with spontaneous bleeding.\n\nPatients must meet inclusion criteria 1 AND 2, or 1 AND 3 in order to be considered for the trial\n\nExclusion Criteria:\n\n1. Patients with Wilson disease, cholestatic liver diseases including primary biliary cholangitis and primary sclerosing cholangitis, all of which are associated with Cu overload;\n2. Patients with fulminant hepatic failure;\n3. Renal failure with a creatinine clearance \\\u003C25 ml\u002Fminute;\n4. Hepatic encephalopathy more than grade 2 (Hepatic Encephalopathy in Chronic Liver Disease, 2014);\n5. MELD score \\>25 to minimize subject dropout due to been too ill;\n6. Serious non-liver related medical illnesses such as cardiopulmonary and renal diseases and non-liver malignancies;\n7. Active alcohol use;\n8. Pregnancy",{"count":120,"type":18},30,[91],"End stage liver disease or cirrhosis is a major cause of mortality in the United States and the world. Other than targeting the underlying cause, such as alcohol cessation and antiviral therapy, very few medical treatments can change the natural history of cirrhosis. Malnutrition is one of the few potentially modifiable factors that have been associated with cirrhosis severity and poor prognosis. The transition metal copper (Cu) is an essential trace metal that must be acquired from diet. Its metabolism is primarily regulated by the liver in its role as a master regulator of nutrients. In 2019, the investigators reported that Cu deficiency defined by below normal serum or liver concentrations occurred in a wide range of liver disorders and was associated with a severe disease phenotype. Improvement in liver function was observed in 2 of the 3 patients who received Cu supplementation. In 2023, the investigators conducted a longitudinal cohort study utilizing clinical, serum and liver explant tissue data from 183 cirrhosis patients. The investigators showed that Cu deficiency was associated with 2-fold higher infection rate and a more than 3-fold increase in the risk of death compared to patients with normal Cu status. These preliminary findings and the well-established importance of Cu in human health prompted the investigators to design the current pilot randomized, placebo-controlled, crossover trial to determine the effect of Cu supplementation on Cu dependent biochemical changes, patient safety and patient reported outcomes in cirrhosis.",[124,125,24,126],"Cirrhosis","Chronic Liver Disease","Infection",[128,129,130],"copper","cirrhosis","malnutrition","2026-03-10",{"date":133,"type":35},"2026-03-13",{"date":135,"type":18},"2026-03-15",{"date":137,"type":18},"2028-12",{"name":139,"class":42},"University of Washington",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":55,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":43},"100554055","phase-2-systemic-therapy-of-open-label-prophylactic-pravastatin-or-pentoxifyllinetocopherol-prevention-of-lymphedema-advancing-to-eventual-fibrosis-an-interventional-registry-embedded-bayesian-randomized-trial-for-radiation-sequelae-stop4-late-fibrose-100554055","NCT06494111","Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline\u002FTocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)","Inclusion Criteria:\n\n• Untreated T0-T4N0-3M0 oropharyngeal squamous carcinoma.\n\n1. Dispositioned to radiotherapy with prescribed dose to unilateral or bilateral neck(s).\n2. Creatinine clearance \\>30mL\u002Fmin\n3. Age ≥18 years. Because no dosing or adverse event data are currently available on the use of pentoxifylline\u002Fpravastatin in participants \\\u003C18 years of age, children are excluded from this study\n4. ECOG performance status ≤2 (Karnofsky ≥60%,)\n5. Participants must have adequate organ and marrow function as defined below\n\n   * absolute neutrophil count ≥1,000\u002FmcL\n   * platelets ≥100,000\u002FmcL\n   * total bilirubin ≤ institutional upper limit of normal (ULN)\n   * AST(SGOT)\u002FALT(SGPT) ≤3 x institutional ULN\n   * creatinine ≤1.5 x institutional ULN\n6. The effects of pentoxifylline\u002Fpravastatin on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female participants, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following.\n\n   * Postmenopausal (no menses in greater than or equal to 12 consecutive months).\n   * History of hysterectomy or bilateral salpingo-oophorectomy.\n   * Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).\n   * History of bilateral tubal ligation or another surgical sterilization procedure.\n   * Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject\u002FPartner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n7. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Active liver disease (Child-Pugh class B-C), cirrhosis, nor active alcoholism.\n2. History of myopathy\u002Frhabdomyolysis.\n3. History of acute myocardial infarction or severe coronary disease.\n4. Pregnant\u002Fpost-menopausal, or male.\n5. History of diabetes mellitus.\n6. Allergy\u002Fhypersensitivity to Hydroxymethylglutaryl-coenzyme A (HMG Co-A) reductase inhibitor and\u002For xanthine derivatives, e.g., caffeine, theophylline, theobromine.\n7. Contraindications for MRI\n8. Participants who are receiving any other investigational agents.\n9. History of allergic reactions attributed to compounds of similar chemical or biologic composition to statins, hemorheologic agents or other agents used in study\n10. Participants with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.",{"count":147,"type":18},295,[57],"To learn if pentoxifylline and vitamin E or pravastatin can reduce radiation-induced lymphedema\u002Ffibrosis.",[151,24],"Lymphedema","2026-02-11",{"date":154,"type":35},"2026-02-13",{"date":156,"type":35},"2025-02-13",{"date":158,"type":18},"2031-03-01",{"name":160,"class":42},"M.D. Anderson Cancer Center",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":171,"conditions":172,"keywords":177,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":43},"100508636","diaphragmatic-function-as-a-biomarker-100508636","NCT05903001","Diaphragmatic Function as a Biomarker","Diaphragmatic Function as a Biomarker in Patients With Respiratory Diseases","DFUNBIO","Inclusion Criteria:\n\n* patient has one of the following lung diseases: COPD, bronchial asthma, pulmonary fibrosis, pulmonary hypertension\n* is 18 years or older\n* is mentally and physically able to understand the study and to follow instructions\n* are legally competent\n* signed declaration of consent\n\nExclusion Criteria:\n\n* BMI \\> 35\n* current or treatments or diseases in the past which could influence the evaluation of the study\n* Expected lack of willingness to actively participate in study-related measures\n* alcohol or drug abuse\n* disc herniation\u002Fprolapse\n* epilepsy\n* wheelchair bound\n* in custody due to an official or court order\n* in a dependent relationship or employment relationship with investigating physician or one of their deputy\n* emergency inpatient hospital stay within 4 weeks before study-specific examinations",{"count":170,"type":18},800,"Dyspnea is among the most common symptoms in patients with respiratory diseases such as Asthma, chronic obstructive pulmonary disease (COPD), Fibrosis, and Pulmonary Hypertension. However, the pathophysiology and underlying mechanisms of dyspnea in patients with respiratory diseases are still poorly understood. Diaphragm dysfunction might be highly prevalent in patients with dyspnea and respiratory diseases. The association of diaphragm function and potential prognostic significance in patients with respiratory diseases has not yet been investigated.",[173,174,24,60,175,176],"Dyspnea; Asthmatic","COPD","Asthma","Dyspnea",[178,174,179,97,180,181],"dyspnea","asthma","pulmonary hypertension","pneumology","2026-01-26",{"date":184,"type":35},"2026-01-28",{"date":186,"type":35},"2023-07-01",{"date":188,"type":18},"2026-12-30",{"name":190,"class":42},"RWTH Aachen University",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":197,"minAge":4,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":55,"phases":200,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":43},"100586237","phase-2-reversing-external-beam-radiotherapy-associated-fibrosis-syndrome-an-interventional-bayesian-adaptive-randomized-controlled-orphan-drug-platform-trial-for-orodental-sequelae-reverse-fibrose-100586237","NCT06912763","Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)","Eligibility Criteria Eligibility criteria (observational registry or randomization)\n\n1. Prior history of head and neck cancer with no active disease.\n2. Treated previously with radiotherapy with prescribed dose (greater or equal to 30Gy) to unilateral or bilateral neck(s)\n3. Detectable CTC-AE G2+ lymphedema\u002Ffibrosis at \\>6 months post-radiotherapy.\n4. No active liver disease (Child-Pugh class B-C), cirrhosis, nor active alcoholism, nor history of ulcers.\n5. No history of myopathy\u002Frhabdomyolysis.\n6. Creatinine clearance \\\u003C30mL\u002Fmin.\n7. No history of acute myocardial infarction or severe coronary disease.\n8. Non-pregnant\u002Fpost-menopausal, or male.\n9. No history of diabetes mellitus\n10. Allergy\u002Fhypersensitivity to HMG Co-A reductase inhibitor and\u002For xanthine derivatives, e.g., caffeine, theophylline, theobromine\n11. No contraindications for magnetic resonance imaging a Subject to the discretion of the treating physician and Principal Investigator (PI), as the MRI may be optional\n\nExclusion Criteria\n\n1. Active liver disease (Child-Pugh class B-C), cirrhosis, nor active alcoholism.\n2. History of myopathy\u002Frhabdomyolysis.\n3. History of acute myocardial infarction or severe coronary disease.\n4. Pregnant\u002Fpost-menopausal, or male.\n5. History of diabetes mellitus.\n6. Allergy\u002Fhypersensitivity to Hydroxymethylglutaryl-coenzyme A (HMG Co-A) reductase inhibitor and\u002For xanthine derivatives, e.g., caffeine, theophylline, theobromine.\n7. Contraindications for MRI Subject to the discretion of the treating physician and Principal Investigator (PI), as the MRI may be optional\n8. Participants who are receiving any other investigational agents.\n9. History of allergic reactions attributed to compounds of similar chemical or biologic composition to statins, hemorheologic agents or other agents used in study\n10. Participants with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.","FEMALE",{"count":199,"type":18},250,[57],"To find out if adding medication can help treat or prevent lymphedema and\u002For fibrosis related to radiation therapy, in survivors of head and neck cancer. Researchers will compare these drugs to find the most effective therapy for preventing or limiting these side effects.",[203,151,204,24],"Fibrosis Syndrome","Head &Amp; Neck Cancer","2026-01-23",{"date":182,"type":35},{"date":208,"type":35},"2025-08-08",{"date":210,"type":18},"2033-03-01",{"name":160,"class":42},{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":219,"sex":15,"minAge":220,"maxAge":4,"enrollmentInfo":221,"targetDuration":223,"studyType":19,"phases":4,"briefSummary":224,"conditions":225,"keywords":232,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":43},"100287699","blood-collection-biorepository-for-liver-disease-research-100287699","NCT03025074","Blood Collection Biorepository for Liver Disease Research","Virology, Immunology and Mechanisms of Liver Disease in Patients With Hepatitis C and Other Liver Diseases","Inclusion Criteria:\n\n* This protocol is to establish a biobank of blood samples from individuals with or without liver diseases including viral hepatitis, liver cancer, NASH, and negative control samples.\n* Children and teenagers will be special populations considered in this protocol.\n\nExclusion Criteria:\n\n* Vulnerable populations such as adults unable to consent, infants, pregnant women or prisoners will not be considered for this research study.",true,"7 Years",{"count":222,"type":18},1000,"1 Day","The purpose of establishing a biorepository is to provide high quality specimens (serum, plasma, buffy coat and liver tissue) for future researchers who are studying the effects that fatty liver and viral diseases have on the liver.",[226,227,228,24,124,229,230,231],"Non-Alcoholic Steatohepatitis(NASH)","Hepatitis C","Hepatitis B","Fatty Liver","Obesity, Childhood","Bariatric Surgery Candidate",[233,234,235,236,237],"Liver Disease","Obesity","Hepatitis","HIV","Hepatology","2025-08-20",{"date":240,"type":35},"2025-08-27",{"date":242,"type":4},"2013-07",{"date":244,"type":18},"2099-12",{"name":246,"class":42},"State University of New York at Buffalo",{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":254,"enrollmentInfo":255,"targetDuration":4,"studyType":55,"phases":257,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":271},"100559238","the-gastric-bypass-stent-system-as-a-treatment-for-hepatic-fibrosis-in-obese-patients-in-european-region-100559238","NCT06561529","The Gastric Bypass Stent System as a Treatment for Hepatic Fibrosis in Obese Patients in European Region","A Prospective, Open-label, Single-arm Clinical Study to Evaluate the Safety and Performance of the Gastric Bypass Stent System as a Treatment for Hepatic Fibrosis in Obese Patients in European Region","Subjects who meet all of the following criteria are eligible for this clinical investigation:\n\n1. Age 18-65 years.\n2. BMI ≥ 30 kg\u002Fm².\n3. Medical history suggests suspected or confirmed NASH fibrosis. Meeting any of the following criteria indicates NASH liver fibrosis:\n\n   * Historical biochemical tests for fibrosis: PRO-C3 \\>14 ng\u002FmL or ELF ≥9\n   * Fibroscan, transient elastography ≥8.5 kPa, controlled attenuation parameter ≥280 dB\u002Fm\n   * Based on existing pathology review, liver biopsy within \\\u003C2 years before the expected randomization shows stage 1B, 2, or 3 fibrosis NASH, with no significant weight change \\>5% or medications likely affecting NAS or fibrosis stage.\n4. Liver biopsy confirming NASH within 6 months before the randomization date, with liver biopsy fibrosis stage 1-3, NAS ≥3, and at least a score of 1 for the following NAS components:\n\n   * Steatosis (0-3 points)\n   * Ballooning (0-2 points)\n   * Lobular inflammation (0-3 points)\n5. Patients who have not achieved effective results after three months of lifestyle modifications and non-invasive treatments (non-diabetic patients have not achieved a weight loss of 5%, diabetic patients have not achieved a weight loss of 3%).\n6. Able and willing to provide informed consent for participation in the clinical investigation and comply with all study procedures and assessments.\n\nSubjects who meet any of the following criteria are not eligible for this clinical investigation:\n\n1. Patients with liver cirrhosis\n2. Patients with secondary obesity; a medical condition that has caused weight gain such as endocrine disorders and hypothalamic disorders.\n3. Chronic, daily use of systemic anti-inflammatory or corticosteroid medications (e.g., ibuprofen, prednisolone) for more than 1 week (not including low-dose aspirin for cardiac prophylaxis or inhaled corticosteroids).\n4. Patients with less than one-year continuous treatment before baseline with hypoglycemic drugs with known weight loss effects (e.g., GLP-1 agonists, SGLT-2 inhibitors, DDP-4 inhibitors).\n5. Patients diagnosed with type 1 diabetes.\n6. Patients with the function of islet β cell basically lost, C-peptide ≤ 1\u002F2 of the normal low limit, or low and flat C-peptide release curve under glucose load.\n7. Patients with significant iron deficiency or iron deficiency anemia upon the Investigator's discretion.\n8. Patients with coagulation dysfunction and chronic, daily use of systemic anti-inflammatory or anti-coagulation medication in the past month (not including low-dose aspirin).\n9. Patients with severe liver and kidney dysfunction, and a serum creatinine concentration ≥ 180 μmol\u002FL.\n10. Patients with Class III heart function of New York Heart Association Functional Classification (NYHA) or higher upon the Investigators evaluation.\n11. Patients who have undergone Endoscopic Retrograde Cholangiopancreatography (ERCP) or have a history of cholecystitis or liver abscess, as assessed by medical history and abdominal ultrasound.\n12. Patients with a duodenal ulcer, gastric ulcer, or previous and existing pancreatitis, as assessed by abdominal ultrasound, gastroscopy (prior to the procedure at Visit 3), and medical history.\n13. Patients with gallstones (diameter ≥ 20 mm) with clinical symptoms as assessed by abdominal ultrasound and medical history.\n14. Patients with on-going thyroid dysfunction, not stabilized despite appropriate treatment.\n15. Patients with hemorrhage or potential hemorrhage in the digestive tract.\n16. Patients with gastrointestinal tract anomalies, such as gastrointestinal tract atresia, or other conditions that would result in failed placement in the gastrointestinal tract, as assessed by gastroscopy (prior to the procedure at Visit 3), abdominal digital gastrointestinal radiography, and medical history.\n17. Patients with a history of bowel obstruction or related diseases in the past year.\n18. Patients with a history of systemic lupus erythematosus or scleroderma.\n19. Patients with severe infections that are not controlled.\n20. Patients with poor general condition and having endoscopic contraindications (as evaluated by the Investigator).\n21. Pregnant women or planning to become pregnant.\n22. Patients with an alcohol dependence or substance abuse.\n23. Patients with unstable psychiatric disorders.\n24. Patients who are enrolled in another investigational study and have not completed the required follow-up period.\n25. Patients with an allergy to any of the components of the investigational device.\n26. Patients with any other conditions evaluated by the Investigators as unsuitable for participating in the clinical investigation.\n27. Patients who are positive for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus as determined by antibodies, deoxy\u002Fribonucleic acid (DNA\u002FRNA), or antigens.\n\nNote: Anti-HCV positive, but HCV-RNA negative HCV patients can be included, based on investigator's judgement, if it's not the primary reason for the fibrosis. Anti-HBc positive, but HBs-Ag negative patients can be included, based on investigator's judgement.","65 Years",{"count":256,"type":18},10,[91],"The Gastric Bypass Stent System is intended to be used in weight loss treatment for obesity and holds potential as a non-invasive technique for managing hepatic fibrosis. This pilot, prospective, single-arm, clinical investigation aims to evaluate the safety and performance of the Gastric Bypass Stent System for hepatic fibrosis treatment in Europe. This clinical investigation and the ongoing clinical investigation (Protocol number: BL-RD08-040) will be used to evaluate the safety and performance of the investigational device for the intended use.",[24,260],"Liver","2025-05-06",{"date":263,"type":35},"2025-05-08",{"date":265,"type":35},"2024-06-13",{"date":267,"type":18},"2025-12",{"name":269,"class":270},"MDCECRO LLC","NETWORK",2,{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":15,"minAge":279,"maxAge":280,"enrollmentInfo":281,"targetDuration":4,"studyType":55,"phases":283,"briefSummary":284,"conditions":285,"keywords":287,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":43},"100309481","screening-at-risk-populations-for-hepatic-fibrosis-with-non-invasive-markers-100309481","NCT03308916","Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers","SIPHON","INCLUSION CRITERIA\n\nPatients are eligible for screening if the following inclusion criteria are fulfilled:\n\n* Age 30-75 years (except the general population, which should be aged 40-75)\n* Informed consent to study investigations\n* Ability to read and write Danish AND (only at-risk patients)\n* Prior or current alcohol overuse, defined as an average intake of ≥24 grams\u002Fday (14 units\u002Fweek) for women and ≥36 grams\u002Fday (21 units\u002Fweek) for men, for at least 5 years; OR\n* Presence of the metabolic syndrome defined by central obesity plus any two of the following four metabolic risk factors: (a) raised triglycerides, (b) reduced HDL cholesterol, (c) raised blood pressure and (d) raised fasting plasma glucose;\\[38\\] OR\n* Type 2 diabetes mellitus defined by either fasting plasma glucose ≥7 mmol\u002FL, HbA1c ≥48 mmol\u002Fmol, a random plasma glucose ≥11.1 mmol\u002FL in the presence of classic diabetes or an oral glucose tolerance test with fasting plasma glucose ≥7.0 mmol\u002FL and\u002For 2 hour plasma glucose ≥11.1 mmol\u002FL.\n\nEXCLUSION CRITERIA\n\nWe will exclude patients from screening in case of:\n\n* Evidence of decompensated liver disease, defined by clinically obvious ascites, overt hepatic encephalopathy, jaundice or large esophageal varices with\u002Fwithout variceal bleeding.\n* Known concurrent liver disease other than ALD and NAFLD.\n* Cancer or other debilitating disease with an expected survival of less than 12 months.\n* Inability to comply with the study protocol.\n\nIn screened patients with liver stiffness ≥8 kPa we will abstain from a liver biopsy in case of:\n\n* Contraindications for a percutaneous liver biopsy\n* Severe alcoholic hepatitis or other hepatic inflammation evidenced by transaminase elevation of more than three times the upper limit of normal.\n* Hepatic congestion or bile duct dilation evidenced by ultrasound.\n* Decrease of TE below 6.0 kPa from screening to time of planned liver biopsy.","30 Years","75 Years",{"count":282,"type":18},6500,[91],"Prospective screening study at Odense University Hospital to assess the effect of transient elastography and other serum and imaging markers of liver fibrosis to detect advanced fibrosis (Kleiner Fibrosis score F3-F4) in patients at risk of non-alcoholic fatty liver disease, alcoholic fatty liver disease, with a control group of participants recruited from the general population.",[286,24],"Liver Diseases, Alcoholic",[288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309],"elastography","screening","non-invasive markers","microbiome","gut-liver-axis","cost-benefit","fibroscan","aixplorer","ultrasound elastography","liver fibrosis","alcoholic liver disease","advanced fibrosis","enhanced liver fibrosis test","direct liver fibrosis markers","ELF","cytokeratin-18","neoepitopes","collagen","NAFLD","ALD","metabolomics","non-alcoholic fatty liver disease","2022-08-29",{"date":312,"type":35},"2022-09-01",{"date":314,"type":35},"2017-10-06",{"date":316,"type":18},"2035-10-30",{"name":318,"class":42},"Maja Thiele",{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":55,"phases":329,"briefSummary":330,"conditions":331,"keywords":334,"overallStatus":336,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":4},"100433533","the-french-national-nafld-cohort-french-patients-with-metabolic-steatosis-100433533","NCT04925362","THE FRENCH NATIONAL NAFLD COHORT (FRench pAtients With MEtabolic Steatosis)","Identification of Clinical and Biological Factors Determining Disease Severity and Disease Progression in NAFLD: \"THE FRENCH NATIONAL NAFLD COHORT\" FRAMES (FRench pAtients With MEtabolic Steatosis)","FRAMES","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Patients with a confirmed diagnosis of NAFLD\n3. Patients affiliated to French social security\n4. Written informed consent signed by the patient\n\nExclusion Criteria:\n\n1. Refusal or inability (lack of capacity) to give informed consent.\n2. Average alcohol ingestion greater than 21\u002F14 units\u002Fweek (males\u002Ffemales) in the preceding 6 months or history of sustained excessive consumption of alcohol in past 5 years.\n3. History or presence of Type 1 diabetes mellitus.\n4. Presence of any other form of chronic liver disease except NAFLD\n5. Recent (within 12 months) or concomitant use of agents known to cause hepatic steatosis (long-term systemic corticosteroids \\[\\>10 days\\], amiodarone, methotrexate, tamoxifen, tetracycline, high dose oestrogens, valproic acid).\n6. Any contra-indication to liver biopsy.\n7. Recent (within 3 months) change in dose\u002Fregimen or introduction of Vitamin E (at a dose ≥400 IU\u002Fday), betaine, s-adenosyl methionine, ursodeoxycholic acid, silymarin or pentoxifylline.\n8. Non-French speaking\u002Funable to access an interpreter.\n9. Patients judged by the investigator to be unsuitable for inclusion in the study (e.g. judged by the physician as unlikely to be compliant with the study protocol).\n10. Pregnant or breastfeeding women\n11. Patient under legal protection measure (tutorship or curatorship) and patient deprived of freedom",{"count":328,"type":18},900,[91],"The main objective of this cohort study is to determine genetic, clinical biologic and metabolic factors associated with patient heterogeneity in regards to severity of NAFLD at diagnosis as well as during the clinical course.\n\n* at diagnosis, with the aim to better characterize patients of different severity and improve our understanding of clinical and histological heterogeneity at diagnosis\n* during the clinical course to better understand and predict disease progression in terms notably of fibrosis progression and progression to cirrhosis",[306,332,333,24,124],"NASH","NASH - Nonalcoholic Steatohepatitis",[335],"Cohort","NOT_YET_RECRUITING","2021-06-07",{"date":339,"type":35},"2021-06-14",{"date":341,"type":18},"2021-06",{"date":343,"type":18},"2036-06",{"name":345,"class":42},"Assistance Publique - Hôpitaux de Paris",{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":353,"enrollmentInfo":354,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":356,"conditions":357,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":372},"100351255","fibro-inflammatory-progression-from-acute-to-chronic-pancreatitis-100351255","NCT03853447","Fibro-inflammatory Progression From Acute to Chronic Pancreatitis","Characterization of Fibro-inflammation During Progression From Acute to Chronic Pancreatitis","Inclusion Criteria:\n\n* Patients with CP (N=50) of any aetiology except gallstone induced CP: CP will be diagnosed based on MANNHEIM criteria .\n* Cohort 2: Patients with their first attack of AP of any aetiology except gallstone induced AP (N=50). The revised Atlanta criteria for acute pancreatitis will be used as diagnostic criteria.\n* Cohort 3: Patients with RAP (N=50) except gallstone induced RAP. RAP is defined as two or more cases of AP as diagnosed by the revised Atlanta Criteria.\n\nExclusion Criteria:","70 Years",{"count":355,"type":18},150,"Observational prospective study evaluating the developement of chronic pancreatitis based on imaging modalities as well as biochemical markers of inflammation, fibrosis and oxidative stress.",[358,359,360,361,362,24],"Pancreatitis","Acute Pancreatitis","Recurrent Pancreatitis","Chronic Pancreatitis","Inflammation","2020-04-07",{"date":365,"type":35},"2020-04-08",{"date":367,"type":35},"2019-02-14",{"date":369,"type":18},"2041-01-01",{"name":371,"class":42},"Copenhagen University Hospital, Hvidovre",3]